SCHEMBL20122933

SCHEMBL20122933

CCn1c2c(-c3ccc(CN4CCOCC4)cc3)cc(Cl)cc2c2ccnc(C)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 3/20 0.43
HRH3 Q9Y5N1 2/20 0.41
ACVR1 Q04771 3/20 0.41
CHUK O15111 2/20 0.40
MAPK8 P45983 2/20 0.40
CDK1 P06493 2/20 0.40
CDK2 P24941 2/20 0.40
CDK9 P50750 2/20 0.40
CASP3 P42574 1/20 0.40
CASP7 P55210 1/20 0.40
PDE4B Q07343 1/20 0.40
LRRK2 Q5S007 1/20 0.39
INSR P06213 1/20 0.39
JAK2 O60674 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20123008 0.91 PDE4B (0.46) PDE4BLRRK2JAK2HSP90AA1HSP90AB1
SCHEMBL30664272 0.91 PDE4B (0.46) PDE4BLRRK2JAK2HSP90AA1HSP90AB1
SCHEMBL20122810 0.86 MAOA (0.49) CAMKK2HRH3CHUKMAPK8INSR
Hydrochloric Acid SCHEMBL29756472 0.86 MAOA (0.48) CAMKK2CHUKMAPK8INSRMEN1
SCHEMBL20123023 0.83 DYRK1A (0.45)
SCHEMBL29756351 0.83 DYRK1A (0.45)
SCHEMBL30664339 0.83 CNR2 (0.52)
SCHEMBL20122978 0.83 CNR2 (0.52)
SCHEMBL20122899 0.81 JMJD6 (0.43) MAPK8LRRK2JAK2TNIKHSP90AA1
SCHEMBL30664237 0.81 JMJD6 (0.43) MAPK8LRRK2JAK2TNIKHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CAMKK2 1944/4885HRH3 342/4885ACVR1 30/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CAMKK2 1944/4885HRH3 342/4885ACVR1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.